Naman Manoj Bhakta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naman Manoj Bhakta has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alison Coady
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA, USA
1 shared publication - Guadalupe Rodriguez
John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA, USA
1 shared publication - Octaviano Zechariah Huron
John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA, USA
1 shared publication - Riddhi Pareek
John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA, USA
1 shared publication - Stanley Akujor
Meharry Medical College School of Medicine, Meharry Medical College, Nashville, USA, USA
1 shared publication
Latest Publications
- Open Access
- 28 April 2026
- Published by MDPI AG in Preprints.org
A Review of Global Antifungal Susceptibility and Resistance Patterns of Candida auris
We conducted a literature review to evaluate global antifungal susceptibility patterns in Candida auris, an emerging multidrug-resistant fungal pathogen of growing clinical concern. A comprehensive search of the literature identified 29 studies reporting min-imum inhibitory concentrations (MICs) and resistance rates across major antifungal classes. Across studies, C. auris demonstrated consistently high resistance to fluconazole, with variable resistance observed among other azoles, amphotericin B, and echi-nocandins, alongside evidence of emerging multidrug resistance. These findings reflect significant geographic variability and highlight ongoing challenges in treatment selec-tion due to inconsistent susceptibility profiles and limited standardized breakpoints. Emerging antifungal agents, including ibrexafungerp and manogepix, demonstrate promising activity and may help address current therapeutic gaps. Overall, the global rise in antifungal resistance among C. auris isolates underscores the narrowing range of effective therapeutic options and reinforces the need for continued surveillance, improved susceptibility testing standardization, and development of novel antifungal agents.
- 28 April 2026
- Published by MDPI AG in Preprints.org
Open AccessA Review of Global Antifungal Susceptibility and Resistance Patterns of Candida auris
We conducted a literature review to evaluate global antifungal susceptibility patterns in Candida auris, an emerging multidrug-resistant fungal pathogen of growing clinical concern. A comprehensive search of the literature identified 29 studies reporting min-imum inhibitory concentrations (MICs) and resistance rates across major antifungal classes. Across studies, C. auris demonstrated consistently high resistance to fluconazole, with variable resistance observed among other azoles, amphotericin B, and echi-nocandins, alongside evidence of emerging multidrug resistance. These findings reflect significant geographic variability and highlight ongoing challenges in treatment selec-tion due to inconsistent susceptibility profiles and limited standardized breakpoints. Emerging antifungal agents, including ibrexafungerp and manogepix, demonstrate promising activity and may help address current therapeutic gaps. Overall, the global rise in antifungal resistance among C. auris isolates underscores the narrowing range of effective therapeutic options and reinforces the need for continued surveillance, improved susceptibility testing standardization, and development of novel antifungal agents.